Dehydration isn't just a summer problem - Here's why Oral Rehydration Solution is a year-round essential
Dehydration is a major health concern that is often ignored and only paid attention to in conditions like diarrhoea, vomiting, or extreme heat exhaustion. Often underestimated, dehydration can quickly become life-threatening.
For common understanding, dehydration occurs when the body loses more fluids than it takes in. This loss may happen due to illness (such as diarrhoea or vomiting), excessive sweating, or simply not drinking enough water. Common symptoms include dry mouth, fatigue, dizziness, and reduced urine output. It is also important to understand that dehydration is not confined to any particular season and needs to be addressed in a timely manner.
Recognising the signs and symptoms of dehydration, and taking steps to prevent and treat it, is crucial for maintaining good health—needless to mention, with due advice from your medical practitioner.
A simple solution to address this big problem of dehydration is Oral Rehydration Solution (ORS). It is important to know and take note that an ORS approved by the World Health Organization (WHO) has a balanced mix of salts and sugars, with an osmolarity of 245 mosmol/litre.
A WHO-approved ORS will always have the osmolarity written on the pack label, and it is important to identify this. This combination optimises the absorption of fluid and electrolytes, which helps quickly restore and replenish the loss.
Contrary to popular belief, high-sugar beverages can worsen dehydration rather than relieve it. These drinks can draw water out of the body, intensifying the feeling of thirst and leaving individuals even more dehydrated.
That's why it's important to choose scientifically formulated solutions like Oral Rehydration Solution, which are designed to rehydrate effectively.
Today, there's a lot of misleading communication in the market that can confuse consumers—many products are labelled with 'ORS' but don't meet the World Health Organisation's recommended formulation. This can lead people to choose products that don't actually provide the right balance of electrolytes and glucose needed to treat dehydration effectively.
It's essential to educate consumers on identifying genuine, scientifically backed ORS solutions.
Managing dehydration effectively means more than just drinking water—it's about consuming the right balance of fluid and electrolytes. A scientifically formulated Oral Rehydration Solution (ORS) contains the ideal mix of glucose and electrolytes that help your body absorb water quickly and restore lost fluids and salts.
Choosing the right Oral Rehydration Solution can make a real difference in how fast you recover from dehydration.
FDC Electral
is committed to combating dehydration by raising awareness about the vital role of Oral Rehydration Salts (ORS). The brand believes in the power of this simple, effective solution to manage and prevent dehydration, and is actively working along with the medical fraternity to educate people and patients at large on its importance and usage.
ELECTRAL , a brand trusted by Doctors & relied upon by millions of people has been rehydrating lives since 1972.
Electral is available in standard packaging of:
21.8 g (to be reconstituted in 1 litre of water)
4.4 g (in 200 ml of water)
200 ml Ready-to-Drink Tetrapak
To meet varying taste preferences, ELECTRAL is now available in five new refreshing flavours:
Fresh Mango
Shikanji Lime
Lychee Burst
Pinacolada Punch
Blackcurrant Blast
As consumer preferences continue to evolve,
FDC
is committed to keeping
ELECTRAL
at the forefront through continuous innovation and the introduction of new offerings that cater to emerging needs.
The above is non-editorial content and TIL does not guarantee, vouch or endorse any of it. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified.
One step to a healthier you—join Times Health+ Yoga and feel the change
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
2 hours ago
- News18
WHO calls for research scale-up towards ending TB in South-East Asia region
New Delhi, Aug 5 (PTI) The WHO on Tuesday called for urgent scale-up of research, innovation and collaboration to accelerate momentum towards ending tuberculosis in the South-East Asia region, which continues to bear nearly half of the global TB burden, accounting for the highest share of cases and deaths worldwide. Experts, national TB programme managers and researchers along with partners and members of civil society began a three-day virtual workshop organised by the World Health Organization (WHO) for advancing research and innovation to accelerate momentum towards ending TB in the WHO South-East Asia region. 'In our Region alone, nearly 5 million people developed TB and close to 600,000 died from the disease in 2023," said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region. Calling for urgent action, she said that achieving the ambitious targets in the WHO End TB Strategy requires collaboration to accelerate research and innovation. It requires the adoption and use of new tools, technologies and drugs. Ensuring timely and equitable access to these innovations remains critical to achieving impacts at scale, leaving no one behind, Boehme said. While the region recorded a significant increase in TB case notifications in 2023, signalling recovery after COVID-19-related setbacks, progress remains insufficient to meet the End TB Strategy targets aligned with the sustainable development goals that call for a 90 per cent reduction in TB deaths and an 80 per cent reduction in incidence by 2030 compared to 2015 levels. Post-COVID-19 pandemic, TB once again reemerged as the world's leading cause of death from a single infectious agent, the WHO said in a statement. It places a disproportionate burden on the poorest and most vulnerable, further exacerbating inequalities. In the South-East Asia region, 30 per cent to 80 per cent of the TB-affected households experience catastrophic costs, underscoring the need for equitable, people-centred approaches and strengthening social protection for the affected, the statement said. Despite these challenges, the WHO South-East Asia region made notable progress. In 2023, 3.8 million new and relapse TB cases were notified, with an 89 per cent treatment success rate for those who began treatment in 2022. Missed cases dropped to 22 per cent in 2023, down from 44 per cent in 2020, the statement said. Backed by strong political commitment, countries in the region are increasingly leveraging new approaches such as artificial intelligence for case detection, computer-aided diagnostics, digital adherence tools and direct benefit transfers for patients, streamlining the social support process. At the same time, several countries are undertaking important research, including epidemiological research to assess the disease burden, the statement said. Bangladesh recently completed a patient cost survey, while findings from India's RATIONS study on the impact of nutrition on TB outcomes and incidence of the disease have contributed to the global guidance. Social and community-based innovations are also playing a vital role. Nepal's TB-Free Pallika initiative and multisectoral coordination mechanisms in Myanmar are helping reach vulnerable populations with person-centred care. A review by the WHO South-East Asia found that member states published over 3,000 TB-related research articles in the past six years, with 60 per cent being original research. However, uptake of research outcomes remains uneven due to knowledge gaps and limited platforms for knowledge exchange and collaborative use, the statement said. 'Our progress is uneven. Research and innovation capacity is varied across the Region, and the results of these efforts are often siloed and unavailable for collaborative use. The rise in drug-resistant forms of TB remains very concerning," said Dr Boehme. The key areas of focus during the virtual consultation include strengthening of South-South collaboration, vaccine preparedness, digital tools for patient care and adherence and efforts to overcome vaccine hesitancy. Participants will also discuss aligning regulatory processes, promoting data sharing and improving platforms for knowledge exchange. A significant emphasis is being placed on identifying operational implementation research priorities, especially in relation to social determinants such as undernutrition and climate change, which influence TB incidence and outcomes. top videos View all 'Several ongoing innovations are attempting to reach out to marginalized and vulnerable groups through active case finding and providing affected families socio-economic support to mitigate catastrophic costs", said Dr Boehme. Highlighting the importance of equity, she added, 'It is incumbent to ensure equitable access to the benefits of research and innovation, including vaccines, medicines and diagnostics." PTI PLB KSS KSS (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 05, 2025, 19:30 IST News agency-feeds WHO calls for research scale-up towards ending TB in South-East Asia region Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
2 hours ago
- Hindustan Times
Early immunisation critical in preventing RSV in infants
Respiratory illnesses in newborns are a major cause of concern, especially when they involve difficulty in breathing. Among the leading causes is Respiratory Syncytial Virus (RSV), a common and highly severe virus that affects the lungs and airways of infants and children under five. This virus often mimics symptoms of a common cold, such as a runny nose or low-grade fever. This similarity can create confusion for parents and health care providers alike, leading to delays in detection and intervention, which allows the illness to rapidly escalate. Vaccination (Getty Images/iStockphoto) For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious. Their tiny airways can get easily blocked by swelling and mucus, leading to lung infections like bronchiolitis or pneumonia. Each year, RSV leads to over 3.6 million hospitalisations and about 100 000 deaths in children under five years of age. As per WHO, most paediatric RSV deaths (97%) occur in low- and middle-income countries where there is limited access to supportive medical care. Even healthy, full-term babies can face complications, and in some cases, require intensive medical care. In India, RSV cases spike during the monsoon and early winter, but the virus can circulate throughout the year. This makes timely protection critical. Medical advancements now offer a way to shield infants through immunisation strategies. While the RSVpreF maternal vaccine is not yet available in India, two monoclonal antibodies have emerged as key preventive options in India. Palivizumab, is administered monthly to high-risk infants such as those born prematurely or with underlying heart or lung conditions. Nirsevimab, on the other hand, is a long-acting monoclonal antibody offering protection with a single-dose. It is designed for all infants regardless of risk category and can be administered soon after birth, before hospital discharge, or during early routine check-ups. Early immunization plays a vital role in protecting infants not just from immediate illness, but also from long-term respiratory complications. Severe RSV infections in the first year of life have been linked to increased risk of recurrent wheezing, asthma, ear infections, and reduced lung function well into adolescence. Infants are especially vulnerable because their immune systems are still developing, and their smaller airways are more easily blocked by inflammation caused by the virus. By providing protection before exposure, through timely use of preventive monoclonal antibodies, we are better equipped to avoid serious outcomes for babies. Parents must understand the importance of stopping the virus before it can take hold, reducing the likelihood of hospitalisation and long-term health issues. For parents and health care providers alike, early immunisation isn't just a seasonal precaution, it's a critical investment in the child's long-term respiratory health and overall well-being. This article is authored by Dr Faisal B Nahdi, paediatrician, Rainbow Children's Hospital, Hyderabad.
Hindustan Times
3 hours ago
- Hindustan Times
What are chikungunya symptoms? CDC issues travel warning for China amid outbreak
Americans travelling to China have been advised to practice utmost caution in the wake of the chikungunya virus outbreak in the country. A Level 2 travel alert was issued by the US Centers for Disease Control and Prevention (CDC) in this regard last week. CDC issued warning for Americans traveling to China after the Chikungunya outbreak.(Unsplash) This comes as more than 7,000 cases of the mosquito-borne virus were reported in the Guangdong province of China, forcing the authorities to put in measures similar to the ones taken during the COVID-19 pandemic period, as per BBC. Among the worst-affected regions in the country is the city of Foshan, where chikungunya patients have been ordered to stay in the hospital until they test negative. They will be discharged at the end of a week-long stay, and their beds are being protected using mosquito nets. Chikungunya: What to know? The viral disease is transmitted mainly through the Aedes mosquitoes. It is caused by the chikungunya virus (CHIKV), which is an RNA virus in the alphavirus genus of the Togaviridae family, as per the World Health Organization (WHO). CHIKV was identified for the first time in the United Republic of Tanzania in 1952, while major outbreaks have been reported in America, Asia, and Africa. A study that came out in Nature in June this year, estimated that around 35.3 million people get infected by Chikungunya on an annual basis across 180 countries and regions. It leads to nearly 3,700 deaths, which is 0.01% of the total cases, as per TIME magazine. The latest outbreak in China has been attributed to imported cases. Liu Qiyong, China CDC's chief expert in vector-borne disease control, told CGTN, 'With the virus spreading globally, imported cases have inevitably reached China.' Chikungunya symptoms The WHO states that chikungunya symptoms are quite similar to dengue and Zika, thus making it difficult to diagnose the disease and accurately determine the total number of infected persons. Also read: Chikungunya outbreak: China on high alert as Guangdong battles over 7,000 cases amid COVID like strict measures Some of the most common symptoms of Chikungunya include high fever, joint pain, headache, muscle pain, as well as joint swelling and rashes. The symptoms usually appear around 4-8 days after the patient is bitten by the infected mosquito. At first, the person gets to witness an 'abrupt onset of fever, frequently accompanied by severe joint pain,' as per the WHO. Notably, the joint pain is often debilitating and can last anywhere from a few days to weeks, months, and even years in some cases. While most of the patients completely recover from the infection, there are cases of eye, heart, and neurological complications that have come up due to the CHIKV infection. FAQs: 1. Why CDC has issued a warning for China? CDC's Level 2 alert, which is designated as 'Practice Enhanced Precautions', came out after China marked over 7,000 cases of chikungunya infections. 2. How are chikungunya patients treated? No specific antiviral treatment is available for the chikungunya virus infections. Usually, doctors give antipyretic and analgesic medications, like paracetamol, for fever and pain, as per the WHO. Also, there are two chikungunya vaccines that have received regulatory approvals, but these are not widely available. 3. Is chikungunya fatal? Severe symptoms and deaths from the viral disease are rare, occurring mostly among young children or elderly people who have co-existing health problems.
